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Circulating Retinol-Binding Protein-4 Concentration
Might Reﬂect Insulin Resistance–Associated Iron
Overload
Jose ´ Manuel Ferna ´ndez-Real, Jose ´ Marı ´a Moreno, and Wifredo Ricart
OBJECTIVES—The mechanisms behind the association be-
tween retinol-binding protein-4 (RBP4) and insulin resistance are
not well understood. An interaction between iron and vitamin A
status, of which RBP4 is a surrogate, has long been recognized.
We hypothesized that iron-associated insulin resistance could be
behind the impaired insulin action caused by RBP4.
RESEARCH DESIGN AND METHODS—Serum ferritin and
RBP4 concentration and insulin resistance were evaluated in a
sample of middle-aged men (n  132) and in a replication
independent study. Serum RBP4 was also studied before and
after iron depletion in patients with type 2 diabetes. Finally, the
effect of iron on RBP4 release was evaluated in vitro in adipose
tissue.
RESULTS—A positive correlation between circulating RBP4
and log serum ferritin (r  0.35 and r  0.61, respectively; P 
0.0001) was observed in both independent studies. Serum RBP4
concentration was higher in men than women in parallel to
increased ferritin levels. On multiple regression analyses to
predict serum RBP4, log serum ferritin contributed signiﬁcantly
to RBP4 variance after controlling for BMI, age, and homeostasis
model assessment value. Serum RBP4 concentration decreased
after iron depletion in type 2 diabetic patients (percent mean
difference 13.7 [95% CI 25.4 to 2.04]; P  0.024). The iron
donor lactoferrin led to increased dose-dependent adipose tissue
release of RBP4 (2.4-fold, P  0.005) and increased RBP4
expression, while apotransferrin and deferoxamine led to de-
creased RBP4 release.
CONCLUSIONS—The relationship between circulating RBP4
and iron stores, both cross-sectional and after iron depletion, and
in vitro ﬁndings suggest that iron could play a role in the
RBP4–insulin resistance relationship. Diabetes 57:1918–1925,
2008
A
dipose tissue is increasingly viewed as an en-
docrine organ that secretes many types of
adipokines (such as leptin, tumor necrosis fac-
tor-, interleukin 6, and adiponectin) that mod-
ulate the action of insulin in other tissues. Retinol-binding
protein-4 (RBP4), a new fat-derived adipokine that specif-
ically binds to retinol, has recently been reported to
provide a link between obesity and insulin resistance (1,2).
Circulating RBP4 levels and adipose tissue RBP4 expres-
sion were raised in several different mouse models of
obesity and insulin resistance. In these animal models,
increasing the circulating levels of RBP4 leads to glucose
intolerance, augmented hepatic gluconeogenesis, and at-
tenuated insulin signaling in skeletal muscle, whereas
knock-out of the RBP4 gene increases insulin sensitivity.
In humans, different authors have reported increased
serum RBP4 concentration in subjects with obesity, insu-
lin resistance, or type 2 diabetes compared with lean
subjects (2–6), although not all studies are concordant. At
least two recent studies (7,8) did not observe a relation-
ship between RBP4 and insulin resistance in women.
Although some problems exist with serum RBP4 measure-
ments (9), RBP4 mRNA was in fact downregulated in
subcutaneous abdominal adipose tissue in postmeno-
pausal women (7). Furthermore, the authors did not see a
relationship between adipose tissue RBP4 expression and
serum RBP4 levels (7).
The mechanisms by which RBP4 induces insulin resis-
tance are not well understood. Treatment of mice with
fenretinide (which facilitates the excretion of RBP4 into
urine) decreased insulin resistance induced by a high-fat
diet (1). Sex and fasting plasma glucose levels seem to be
independent determinants of plasma RBP4 concentration.
Many adipokines have been found to be sexually dimor-
phic. Both leptin and adiponectin are increased in serum
of women compared with men. This observation has been
explained on the basis of different fat amounts and the
inﬂuences of sex hormones (10,11). Plasma RBP4 concen-
trations, however, exhibit an opposite pattern. The median
(range) for RBP4 in plasma was 21.0 g/ml (10.7–48.5) for
men and 18.1 g/ml (9.3–34.6) for women (P  0.001) (3).
Since data regarding menopausal status were not avail-
able, the authors arbitrarily subdivided sex groups at 50
years of age. Plasma RBP4 levels in women aged 50
years were found to be signiﬁcantly higher than those in
women aged 50 years. However, no such age-associated
difference in RBP4 plasma levels was observed in men.
Thus, the pattern of serum RBP4 concentrations in serum
resembles that of iron stores: higher in men than women,
in whom iron stores increase after menopause. Further-
more, treatment with fenretinide induces a dose-depen-
dent peripheral anemia evidenced by erythrocytopenia
and decreased hemoglobin concentration and packed cell
volume in addition to excretion of RBP4 into urine (12).
On the other hand, RBP4 is an indicator of vitamin A
(retinol) intake (13,14). The interaction between vitamin A
and iron status is well known. For instance, vitamin A
deﬁciency may impair iron metabolism and aggravate
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1918 DIABETES, VOL. 57, JULY 2008anemia (15–17). In fact, iron deﬁciency anemia and vita-
min A deﬁciency often coexist (15–17).
In the last years, increased iron intake and raised iron
stores have been recognized as signiﬁcant, independent
contributors to insulin resistance in the general population
and in patients with type 2 diabetes (rev. in 18,19). On the
other hand, iron supplementation signiﬁcantly increased
plasma retinol and RBP4 (20). Given the interactions
between vitamin A and iron, we hypothesized that raised
iron stores could be behind the association between
increased serum RBP4 concentration and insulin resis-
tance. We found that serum ferritin concentration was
positively associated with serum RBP4 concentration in
two independent studies. Given these cross-sectional ob-
servations, we further aimed to explore these interactions
in vitro and to evaluate serum RBP4 concentration after
iron depletion in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Study of RBP4 in apparently healthy men. We studied 132 nondiabetic
men who were consecutively enrolled in a prospective study of cardiovascular
risk factors (21). All subjects reported that their body weight had been stable
for at least 3 months before the study. A food-frequency questionnaire was
obtained from all subjects. None of the subjects were taking any medication
or had any evidence of metabolic disease other than obesity. Inclusion criteria
were 1) BMI 40 kg/m
2, 2) absence of any systemic disease, and 3) absence
of clinical symptoms and signs of infection in the previous month by
structured questionnaire to the patient. Informed consent was obtained from
all subjects. The hospital ethics committee approved the study.
BMI was calculated as weight (in kilograms) divided by square of height (in
meters). The subjects’ waist was measured with a soft tape midway between
the lowest rib and the iliac crest. The hip circumference was measured at the
widest part of the gluteus region. The waist-to-hip ratio was then calculated.
Blood pressure was measured in the supine position on the right arm after a
10-min rest; a standard sphygmomanometer of appropriate cuff size was used,
and the ﬁrst and ﬁfth phases were recorded. Values used in the analysis are the
average of three readings taken at 5-min intervals. Patients were requested to
withhold from alcohol and caffeine during at least 12 h before the different
tests. All subjects had fasting plasma glucose 7.0 mmol/l. Type 2 diabetes
was ruled out by an oral glucose tolerance test, according to criteria from the
American Diabetes Association.
Replication study. All subjects, recruited among hospital and lab staff, were
of Caucasian origin and reported that their body weight had been stable for at
least 3 months before the study. They had no systemic disease and all were
free of any infections in the previous month before the study. Liver and renal
diseases were speciﬁcally excluded by biochemical work-up.
Study of RBP4 release in adipose tissue explants. To gain further insight
of the RBP4-iron relationship, we hypothesized that iron donors (holotrans-
ferrin and lactoferrin) and iron buffers (apotransferrin and deferoxamine)
could inﬂuence RBP4 release from adipose tissue. To this end, adipose tissue
was obtained from 14 obese subjects (10 visceral and 4 subcutaneous fat
depots) undergoing open abdominal surgery (gastrointestinal bypass) under
general anesthesia after an overnight fast. The mean age was 45 years (range
41–55) and the BMI 44.9  12.4 kg/m
2. Medical histories, physical examina-
tions, electrocardiogram, and blood screening showed that all patients were in
good health. None of the subjects had a history of hepatic or renal disorders.
The study had the approval of the ethical committee, and all patients gave
informed written consent.
Samples of adipose tissue were immediately transported to the laboratory
(5–10 min). The handling of tissue was carried out under strictly aseptic
conditions. The tissue was cut with scissors into small pieces (5–10 mg) and
incubated in buffer plus albumin (3 ml/g of tissue) for 5–30 min. After
incubation, the tissue explants were centrifuged for 30 s at 400g. Then 100 mg
of minced tissue was placed into 1 ml M199 (Life Technologies, Invitrogen)
containing 10% fetal bovine serum (Hyclone, Thermo Fisher Scientiﬁ), 100
unit/ml penicillin (Life Technologies, Invitrogen), and 100 g/ml streptomycin
(Life Technologies, Invitrogen) and incubated for 48 h in suspension culture
under aseptic conditions (18,19).
We performed the follow treatments: vehicle, 10 mol/l human transferrin
(T0665; Sigma-Aldrich), 10 mol/l human apolipoprotein-transferrin (T1147;
Sigma-Aldrich), human lactoferrin (L4894; Sigma-Aldrich), and 10 mol/l
metformin (D5035; Sigma-Aldrich). The effects of 20 mol/l deferoxamine
mesylate (D9533; Sigma-Aldrich) were also tested in six explants. In indepen-
dent experiments, we evaluated the dose-dependent effects of lactoferrin (1,
10, and 100 mol/l) and the time course using 10 mol/l of lactoferrin at times
0, 1, 3, 6, 12, 24, and 48 h. The supernatants were collected, aliquoted, and
stored at 80°C until assay. Circulating RBP4 in supernatants was analyzed by
competitive enzyme-linked immunosorbent assay (AdipoGen, Seoul, Korea)
according to the manufacturer’s instructions. Sensitivity of the method was 1
ng/ml. The intra- and interassay coefﬁcients of variation were between 2 and
10%. Circulating adiponectin in supernatants was analyzed by enzyme-linked
immunosorbent assay (Linco Research, St. Charles, MO), according to the
manufacturer’s instructions. Sensitivity of the method was 0.78 ng/ml. The
intra- and interassay coefﬁcients of variation were between 2 and 10%. To
evaluate cell integrity, lactate deshidrogenase (LDH) activity was analyzed by
a cytotoxicity detection kit (LDH) (Roche Diagnostics, Mannheim, Germany),
according to the manufacturer’s instructions.
RBP4 expression analysis in adipose tissue explants. Total RNA from
adipose tissue was isolated using the RNeasy Lipid Tissue Mini Kit (Qiagen
Science, Gaithersburg, MD) according to the manufacturer’s protocol. Quan-
tity and integrity of RNA were measured using the 2100 Bioanalyzer (Agilent
Technologies, Waldbronn, Germany), assuring that the values measuring
integrity were 8.5 in all samples. First-strand cDNA was synthesized from 1
g total RNA with a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). Quantitative real-time TaqMan PCR was per-
formed with commercial inventoried primers and 6-carboxyﬂuorescein dye–
labeled TaqMan minor groove binder probes (Applied Biosystems) for RBP4
and cyclophilin A (used as endogenous control) and 2	 Universal PCR Master
Mix (Applied Biosystems). Each TaqMan reaction contained 4 l of cDNA,
corresponding to 100 ng of total RNA, in a total reaction volume of 25 l. The
relative expression was determined by the comparative threshold method, as
described in the ABI Prism 7700 User Bulletin (P/N 4303859) from Applied
Biosystems.
Study of changes in circulating RBP4 after iron depletion in type 2
diabetes. The study subjects (n  13 male patients; [means  SD] age 55.8 
8.4 years; BMI 29.1  3.48 kg/m
2; A1C 6.1  0.8%) are part of a well-
characterized sample of high-ferritin type 2 diabetic patients subjected to
blood letting and previously reported by us (22,23). In the original cohort,
patients with elevated serum ferritin concentrations were randomized to
either iron depletion (intervention group; n  13) or to observation (n  15)
according to a randomization table that included age, BMI, and A1C. The two
groups were also matched for pharmacological treatment and chronic diabe-
tes complications. The iron depletion intervention consisted of three blood
extractions (500 ml each) at 2-week intervals. The patients were studied at
baseline and at 4 and 12 months after the last phlebotomy. In the present
study, available serum samples were used for measuring RBP4 in 6 patients in
the intervention group and 12 patients in the observation group at baseline
and 12 months after iron depletion or follow-up. The clinical and biochemical
characteristics of these subjects were comparable with those of the initial
cohort (22). Subjects were studied in the postabsorptive state.
Study of insulin sensitivity. The experimental protocol started between
8:00 and 9:30 A.M. after an overnight fast. All of the subjects were on a
weight-maintaining diet before the test. A bolus of human actrapid insulin (0.1
unit/kg; Novo Nordisk, Copenhagen, Denmark) was administered into an
antecubital vein, and blood was sampled from a vein on the dorsum of the
same hand. To arterialize the venous blood, the hand was placed on a hot box
at a constant temperature of 40°C for 20 min before the start of the study and
kept there until the end of the test. Sampling was carried out every minute
until 15 min after the injection of insulin. Insulin sensitivity was indicated by
the ﬁrst-order rate constant for disappearance rate of glucose estimated from
the slope of the regression line of the logarithm of blood glucose against time
during the ﬁrst 3–15 min.
Analytical methods. Serum glucose concentrations were measured in dupli-
cate by the glucose oxidase method with the use of a Beckman Glucose
Analyser II (Beckman Instruments, Brea, CA). The coefﬁcient of variation was
1.9%. Total serum cholesterol was measured through the reaction of choles-
terol esterase/cholesterol oxidase/peroxidase. HDL cholesterol was quantiﬁed
after precipitation with polyethylene glycol at room temperature. Total serum
triglycerides were measured through the reaction of glycerol-phosphate-
oxidase and peroxidase. Serum insulin levels during the frequently sampled
intravenous glucose tolerance test were measured in duplicate by monoclonal
immunoradiometric assay (IRMA; Medgenix Diagnostics, Fleunes, Belgium).
Intra- and interassay coefﬁcients of variation were 6%. Serum transferrin and
ferritin were measured as previously reported (22). Whole-blood hemoglobin
and hematocrit were determined by routine laboratory tests (Coulter Elec-
tronics, Hialeah, FL).
Serum RBP4 concentrations in the clinical study were measured by
nephelometry (Dade Behring, Marburg, Germany). Sensitivity of the method is
0.01 mg/dl. The intra- and interassay coefﬁcients of variation were 3.1% and
2.2%, respectively. The change in serum RBP4 after iron depletion was
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above in the in vitro study.
Statistical methods. Descriptive results of continuous variables are ex-
pressed as means  SD. Before statistical analysis, normal distribution and
homogeneity of the variances were evaluated using Levene’s test, and
variables were given a log transformation if necessary. These parameters
(RBP4, homeostasis model assessment [HOMA], and triglycerides) were
analyzed on a log scale and tested for signiﬁcance on that scale. The anti–log-
transformed values of the means are reported in the Tables. The study also
had a 67% power to detect signiﬁcant differences of at least 1 SD in serum
RBP4 concentration between obese and nonobese subjects. The relationships
between variables were tested using Pearson’s test and multiple linear
regression analysis (stepwise). We used 

2 test for comparisons of propor-
tions and unpaired or paired t tests for comparisons of quantitative variables.
The analyses were performed using the program SPSS (version 11.0).
RESULTS
RBP4 and serum ferritin in apparently healthy sub-
jects. Main characteristics of study subjects classiﬁed
according to RBP4 quartiles are shown on Table 1. HOMA
value was signiﬁcantly associated with log serum ferritin
(r  0.22, P  0.01) but not with serum RBP4 concentra-
tion (r  0.07, P  0.4). This could be due to the narrow
range of HOMA index in this population. However, when
lean subjects (BMI 25 kg/m
2, n  50) were excluded
from the analyses, the HOMA value was signiﬁcantly
associated with both log serum ferritin (r  0.32, P 
0.003) and serum RBP4 (r  0.23, P  0.04) (n  82). This
suggests a threshold effect (i.e., that adipose tissue mass
needs to exceed a certain threshold for RBP4 release to
associate with HOMA). Accordingly, we explored HOMA
value and log serum ferritin according to RBP4 quartiles.
Subjects with serum RBP4 concentration in the two upper
quartiles showed signiﬁcantly higher HOMA index in par-
allel to log serum ferritin concentrations (Fig. 1). In
addition, those subjects in the highest quartile also had
signiﬁcantly higher serum transferrin (Table 1). A signiﬁ-
cant and positive correlation between circulating RBP4
and log serum ferritin (r  0.35, P  0.0001) was observed
(Fig. 2). On multiple regression analyses to predict serum
RBP4, log serum ferritin independently contributed to 5%
of RBP4 variance (0.22, P  0.02) after controlling for
BMI (P  0.3), age (P  0.3), and HOMA value (P  0.7).
Replication study. In this independent replication study,
we evaluated 20 men and 13 women similar in age (34.7 
4 vs. 33.7  4.8 years, P  0.5), BMI (26.5  3.4 vs. 26.4 
5.5 kg/m
2, P  0.9), fasting glucose (5.36  0.83 vs. 5.26 
0.96 mmol/l, P  0.7), and fasting insulin (8.4  4.9 vs.
8.6  4.5 mU/l, P  0.9). Log serum ferritin correlated
positively with serum RBP4 concentration (r  0.61, P 
0.0001). Serum RBP4 concentration was higher in men
than women (P  0.001) in parallel to increased ferritin
levels (P  0.0001) (Fig. 3).
Study of changes in circulating RBP4 after iron de-
pletion. The two groups of subjects (all men) were similar
in age, glycated hemoglobin, and baseline serum ferritin
concentrations. Serum RBP4 concentration tended to in-
crease over time in type 2 diabetic patients at follow-up
(no intervention) (mean 6.8  3%), while RBP4 de-
creased after iron depletion (mean 6.8  5% [percent
mean differences and 95% CI for the difference: 13.7
{25.4 to 2.04}], P  0.024) (Fig. 4).
Insulin sensitivity was essentially unchanged (1.95 
0.86 vs. 1.98  0.79 mg  dl
1  min
1, P  0.9) in the
control group, while this parameter tended to increase
after iron depletion (1.03  0.65 vs. 2.46  0.8 mg  dl
1 
min
1, P  0.06). Interestingly, the lower the serum RBP4
concentration at follow-up the higher the increase in
insulin sensitivity (r  0.83, P  0.02).
Study of RBP4 release in adipose tissue explants.
RBP4 was spontaneously secreted by adipose tissue ex-
plants (median [interquartile range] 216.9 ng/ml [63.1–
427]). After metformin treatment, RBP4 did not change
signiﬁcantly (191.4 ng/ml [61.4–508]). Lactoferrin (10
mol/l) led to signiﬁcantly increased (2.4-fold) RBP4 re-
lease into the media (450 ng/ml [177.2–809.9], P  0.005)
(Fig. 5A). After 48 h of incubation, lactoferrin treatment
led to a 1.32-fold higher RBP4 expression (P  0.01) (Fig.
5B). There were no signiﬁcant differences between fat
depots. Lactoferrin increased RBP4 release dose depen-
dently (Fig. 6A). In the time-course experiments, the
increase in expression and secretion of RBP4 was ob-
served in the ﬁrst hour after lactoferrin treatment and
TABLE 1
Clinical and laboratory variables of study subjects according to serum RBP4 quartiles
RBP4 quartiles
ANOVA P value Q1 Q2 Q3 Q4
n 33 33 33 33
RBP4 (mg/dl) (95% CI for mean) 2.44–2.79 3.40–3.54 3.92–4.06 4.85–5.39 0.00001
Age (years) 51.5  12.4 50  9.4 52  10.8 49.6  10.9 0.8
BMI (kg/m
2) 27.2  3.4 28.2  4 27.3  3.5 27.8  2.9 0.7
Waist-to-hip ratio 0.93  0.07 0.94  0.06 0.93  0.06 0.93  0.06 0.9
Systolic blood pressure (mmHg) 129.7  12.7 125.4  15 122.7  17.2 128.4  15 0.3
Diastolic blood pressure (mmHg) 82.3  8.1 81.1  9.7 77.8  13.4 81.8  10.9 0.4
Fasting glucose (mg/dl) 97  12 99.1  12.1 97  8 97.7  11.5 0.9
Fasting insulin (mU/l) 7.17  3.47 7.54  3.31 9.34  5.07 9.34  5.84 0.4
HOMA 1.62  0.81 1.67  0.73 2.2  1.3* 2.32  1.6* 0.2
Cholesterol (mg/dl) 200.7  38.3 210.8  51.7 207.2  35.7 210  29.8 0.8
HDL cholesterol (mg/dl) 49.6  8.8 50.4  13.9 50.3  11.1 53.3  11.5 0.6
Log fasting triglycerides 1.94  0.19 2.03  0.25 1.92  0.2 1.93  0.25 0.3
Log serum ferritin 1.95  0.43 2.03  0.38 2.09  0.31† 2.21  0.37†‡ 0.10
Transferrin (mg/dl) 238.3  40 266.7  43 256  47.4 272.8  34.1§ 0.07
Data are means  SD, unless otherwise indicated. *P  0.026 when both upper quartiles were compared with the remaining subjects. †P 
0.03 when both upper quartiles were compared with the remaining subjects. ‡P  0.03 when compared with remaining subjects. §P  0.04
when compared with remaining subjects.
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ments (Fig. 6B).
Incubation with human apolipoprotein–transferrin (10
mol/l) led to decreased RBP4 concentration in the media
in comparison with vehicle (169.2 ng/ml [interquartile
range 54.5–351], P  0.04) (Fig. 5A). Human transferrin (10
mol/l) treatment did not lead to signiﬁcant changes in
RBP4 concentration (227.82 ng/ml [62.7–449.3]) (Fig. 5A).
Incubation with deferoxamine (20 mol/l) led to signiﬁ-
cantly decreased RBP4 release into the media (139 ng/ml
[130.9–154.7] vs. 168 ng/ml [141.4–220], deferoxamine
versus vehicle, respectively; P  0.02) (Fig. 5C). RBP4
expression after deferoxamine treatment was decreased
by 30% (P  0.03) (Fig. 5D).
Adiponectin concentration in the supernatants (112.9
ng/ml [interquartile range 85.8–126.9]) did not change
signiﬁcantly after the different treatments were evaluated.
LDH activity was similar after all treatments tested (0.39
[0.33–0.48] units of absorbance at 492 nm) and did not
change signiﬁcantly during the time-course experiments
(Fig. 6C).
DISCUSSION
The lipocalins (such as RBP4) are a large, diverse, but
relatively poorly understood family of small extracellular
proteins that are characterized by the ability to bind small
hydrophobic molecules, such as retinol (RBP4), and by
their binding to speciﬁc cell surface receptors. These
general properties suggest that such proteins are appro-
priate transporters for transferring biologically hazardous
molecules in a safe and controlled manner between cells.
In this study, we report that circulating RBP4 concen-
tration was associated with iron stores in middle-aged men
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trary to other adipokines (10,11), serum RBP4 concentra-
tion was higher in men than women (as previously
described [3]). These ﬁndings were in parallel to increased
serum ferritin of men. Iron depletion led to signiﬁcantly
decreased serum RBP4 concentration in comparison with
the observational group. Interestingly, the lower the RBP4
concentration, the higher the change in insulin sensitivity
after iron depletion. These changes resembled those in-
duced by fenretide. In addition to increased urinary excre-
tion of RBP4, fenretide also leads to decreased total
hemoglobin and anemia (13), hinting at iron-induced de-
pletion as another potential mechanism through which
fenretide could improve insulin sensitivity. Furthermore,
lactoferrin, a well-known iron transport protein and iron
donor (24), led to signiﬁcant RBP4 release in a dose-
dependent manner and to increased RBP4 expression in
adipose tissue explants. Our ﬁndings imply that iron
supplementation leads to enhanced RBP4 release from
cells due to enhanced transcription. We also performed a
study of the time-course effects of lactoferrin, together
with appropriate controls for cell integrity (LDH release)
(Fig. 6) and speciﬁcity (adiponectin). Consistent with
these observations, RBP4 was signiﬁcantly associated
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P  0.004, n  56; data not shown). Apotransferrin (a
well-known iron buffer) led to signiﬁcant decrease in RBP4
release. It could be argued that apotransferrin does not
bind to transferrin receptors but would bind extracellular
free iron, forming holo-transferrin, which would then be
capable of binding to the transferrin receptor and inter-
nalize and actually increase cellular iron stores. However,
holo-transferrin did not show signiﬁcant effects on RBP4
release. Furthermore, deferoxamine (another iron buffer)
also led to signiﬁcantly decreased RBP4 release and
expression.
Our ﬁndings imply that iron stores could independently
affect RBP4 levels and insulin sensitivity. However, we
cannot exclude that iron-dependent insulin resistance is
inﬂuenced by concomitant changes in RBP4. To our knowl-
edge, no study has previously suggested this association.
The lack of effect of holo-transferrin was relatively
unexpected. However, the stage-speciﬁc capture of differ-
ent iron transporters is well recognized (25). Iron delivery
to cells is not only mediated by different proteins but also
has different functions at different cellular stages and is
dependent on cell type and cell stage (25). Transferrin
transfers iron from circulation, while lactoferrin has a very
acidic pH sensitivity and trafﬁcs late endosomes into a
clearly different intracelluar route (26).
RBP4 has been used clinically as a rapid turnover
protein for assessing the short-term ﬂuctuation of nutri-
tional states. RBP4 is the only speciﬁc transport protein
for retinol (vitamin A) in circulation (27). It is produced by
hepatocytes, which are believed to contribute to a large
part of circulating RBP4, although adipocytes have the
second-highest expression level (28). Elevated RBP4 lev-
els have been recently reported in subjects with insulin
resistance and type 2 diabetes (2–8). Serum ferritin is also
known to be increased in insulin resistance and type 2
diabetes (18,19).
A positive relationship between ferritin and RBP and
alterations of RBP in diabetes have been described in
earlier studies (15,20,29,30). An interaction between iron
and vitamin A intake has also been well recognized in the
past (15–17). Rosales et al. (31) showed that the distribu-
tion of retinol through various body compartments is
dependent on iron status, with higher concentrations of
vitamin A in the livers of food-restricted control rats than
in those of iron-deﬁcient rats. These authors also demon-
strated decreased plasma RBP concentration in iron-
deﬁcient rats (31). Iron deﬁciency lowers serum retinol,
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FIG. 5. A: Effects of lactoferrin (LTF), apolipoprotein-transferrin (Apo-TF), and holotransferrin (TF) on RBP4 release from adipose tissue
explants compared with vehicle (C). B: Effects of lactoferrin (10 mol/l) on RBP4 expression. Effects of deferoxamine (20 mol/l) (DFO) on RBP4
release (C) and RBP4 expression in adipose tissue explants (D).
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DIABETES, VOL. 57, JULY 2008 1923and vitamin A accumulates in the liver as retinyl esters,
probably due to impaired activity of hepatic acid retinyl
ester hydrolase, an iron-dependent enzyme (31). Consis-
tent with the data from these animal studies, long-term
supplementation with iron caused large increases in serum
retinol in children (20). Supplements containing iron alone
increased plasma retinol in iron-deﬁcient children (plasma
ferritin 12 g/l) (20). It has been suggested that low
plasma retinol concentrations were in fact caused by iron
deﬁciency rather than vitamin A deﬁciency (20). Deﬁ-
ciency and supplementation of iron have different effects
on the complicated intrahepatic balance between cellular
uptake and mobilization of vitamin A and, hence, RBP4
(31–33).
On the other hand, vitamin A supplementation improves
indicators of iron nutritional status, such as serum iron,
transferrin, transferrin saturation, hematocrit, and hemo-
globin, suggesting that vitamin A affects iron metabolism
(34–36). In children, plasma hemoglobin and ferritin con-
centrations were correlated with plasma retinol and RBP
(35).
Frequent blood donations, leading to decreasing iron
stores, have been demonstrated to constitute a protective
factor for the development of diabetes (37). Iron stores
also appear to predict an increased incidence of type 2
diabetes (38). We previously described a statistically sig-
niﬁcant increase in insulin sensitivity after iron depletion
(from 2.30  1.81 to 3.08  2.55 mg  dl
1  min
1 at 4
months to 3.16  1.85 mg  dl
1  min
1 at 12 months; P 
0,045) in contrast to patients subjected to observation in
whom insulin sensitivity did not signiﬁcantly change (from
3.24  1.9 to 3.26  2.05 mg  dl
1  min
1 at 4 months to
2.31  1.35 mg  dl
1  min
1 at 12 months) (22). The
mechanisms by which iron depletion leads to improved
insulin sensitivity are not well understood. Decreased
oxidative stress, transition metal–catalyzed reactions, and
reactive oxygen species have been hypothesized as poten-
tially involved. In addition, decreased RBP4 could also
play a role.
According to the ﬁndings described in the present
article and those present in the literature, a scenario can
be envisioned in which the intake of vitamin A and iron
lead to reciprocal changes in nutritional indicators of their
intake (RBP4 and ferritin). Given the well-known interac-
tion between iron and vitamin A status, increased RBP4
concentration could be a marker of insulin resistance–
associated iron overload (18,19).
In summary, the relationship between circulating RBP4,
RBP4 release after iron modulation in adipose tissue
explants, and decreased serum RBP4 after iron depletion
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FIG. 6. a) Effects of lactoferrin on RBP4 secretion from adipose tissue explants in a dose-dependent manner (A) and effects of lactoferrin (10
mol/l) during time course experiments (B). C: LDH activity during these latter experiments. The results show that an iron donor (lactoferrin)
led to signiﬁcant RBP4 release dose and time dependently.
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resistance relationship.
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